{
    "clinical_study": {
        "@rank": "87266", 
        "arm_group": {
            "arm_group_label": "S-1 plus DC-CIK", 
            "arm_group_type": "Experimental", 
            "description": "Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.\nDC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis 3 days before administrating S-1 , and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the antitumor effect and safety of clinical\n      effectiveness S-1 plus dendritic cell activated Cytokine induced killer treatment (DC-CIK)\n      for advanced gastric cancer."
        }, 
        "brief_title": "Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically/cytologically confirmed recurrent or metastatic gastric or\n             esophagogastric junctional adenocarcinoma\n\n          -  Between 18 and 80 years old\n\n          -  Capable of oral intake\n\n          -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors\n             (RECIST) criteria\n\n          -  Karnofsky Performance Status (KPS) \u2265 70%\n\n          -  Normal functions of heart, lung and bone marrow\n\n          -  Adequate hematological profile\uff1a Hemoglobin \u2265 9.0 g/dL Absolute granulocyte count \u2265\n             1,500/mm3 Platelet count \u2265 100,000/mm3\n\n          -  Adequate hepatic function Total bilirubin level\u2264 3.0 times the upper limit of normal\n             (ULN) Transaminases AST (SGOT) and ALT (SGPT) \u2264 2.5 times ULN\n\n          -  Adequate renal function(normal serum creatinine level)\n\n          -  A life expectancy\u2265 2 months\n\n          -  Informed consent signed\n\n        Exclusion Criteria:\n\n          -  Current enrollment in another clinical study with an investigational agent. Patients\n             participating in surveys or observational studies are eligible to participate in this\n             study\n\n          -  Any radiotherapy or surgery within the previous 4 weeks\n\n          -  Symptomatic brain metastasis not controlled by corticosteroids\n\n          -  Bone marrow metastasis\n\n          -  Active infection\n\n          -  Serious complications\n\n          -  Receiving a concomitant treatment with drugs interacting with S-1. The following\n             drugs are prohibited because there may be an interaction with S-1: phenytoin,\n             potassium warfarin , flucytosine, cimetidine and folinic acid.\n\n          -  Pregnant or lactation women, or women with known or suspected pregnancy and men who\n             want let to pregnancy\n\n          -  Ineligible for the study at the discretion of investigators"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01783951", 
            "org_study_id": "S1+DC CIK- G"
        }, 
        "intervention": {
            "arm_group_label": "S-1 plus DC-CIK", 
            "intervention_name": "S-1 plus DC-CIK", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Gastric cancer", 
            "S-1", 
            "DC-CIK"
        ], 
        "lastchanged_date": "February 1, 2013", 
        "location": {
            "contact": {
                "email": "renjun9688@yahoo.com", 
                "last_name": "Jun Ren, MD,PhD", 
                "phone": "86-10-63926317"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100038"
                }, 
                "name": "Capital Medical University Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "renjun9688@yahoo.com", 
            "last_name": "Jun Ren, MD, PhD", 
            "phone": "86-10-63926317"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival\uff08PFS\uff09", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01783951"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Capital Medical University", 
            "investigator_full_name": "Jun Ren MD, PhD", 
            "investigator_title": "Director,Capital Medical University (CMU)Cancer Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks"
            }, 
            {
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Every 3 weeks"
            }, 
            {
                "description": "Evaluation of quality of life will be performed every 2 cycles (6 weeks) from baseline to the end of treatment.", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Capital Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Capital Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}